tiprankstipranks
Trending News
More News >
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
US Market

Adverum Biotechnologies (ADVM) Stock Forecast & Price Target

Compare
620 Followers
See the Price Targets and Ratings of:

ADVM Analyst Ratings

Strong Buy
4Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Adverum
Biotechnologies
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ADVM Stock 12 Month Forecast

Average Price Target

$17.00
▲(472.39%Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Adverum Biotechnologies in the last 3 months. The average price target is $17.00 with a high forecast of $30.00 and a low forecast of $4.00. The average price target represents a 472.39% change from the last price of $2.97.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.33,5.381538461538462,7.433076923076923,9.484615384615385,11.536153846153846,13.587692307692308,15.63923076923077,17.69076923076923,19.74230769230769,21.793846153846154,23.845384615384617,25.896923076923073,27.948461538461537,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.33,4.381538461538462,5.433076923076923,6.484615384615385,7.536153846153846,8.587692307692308,9.63923076923077,10.69076923076923,11.742307692307692,12.793846153846154,13.845384615384615,14.896923076923077,15.948461538461538,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.33,3.3815384615384616,3.433076923076923,3.4846153846153847,3.536153846153846,3.5876923076923077,3.6392307692307693,3.690769230769231,3.7423076923076923,3.793846153846154,3.8453846153846154,3.896923076923077,3.9484615384615385,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.9,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.89,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$17.00Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ADVM
TipRanks AITipRanks
Not Ranked
TipRanks
$2.5
Sell
-15.82%
Downside
Reiterated
06/07/25
Adverum Biotechnologies' overall stock score is predominantly affected by its poor financial performance and bearish technical indicators. The negative P/E ratio further highlights valuation concerns. The subtenant default situation adds potential operational risks, requiring close monitoring. Immediate improvements in financial health and strategic adjustments are essential for enhancing the stock's prospects.
TD Cowen Analyst forecast on ADVM
Joseph ThomeTD Cowen
TD Cowen
Buy
Reiterated
05/15/25
Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec's Advancements in Wet AMD Treatment
H.C. Wainwright Analyst forecast on ADVM
Matthew CaufieldH.C. Wainwright
H.C. Wainwright
$30
Buy
910.10%
Upside
Reiterated
05/15/25
Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Adverum Biotechnologies (ADVM)
RBC Capital Analyst forecast on ADVM
Lisa WalterRBC Capital
RBC Capital
$5$4
Hold
34.68%
Upside
Reiterated
05/14/25
Adverum Biotechnologies (ADVM) Gets a Hold from RBC Capital
Truist Financial Analyst forecast on ADVM
Joon LeeTruist Financial
Truist Financial
Buy
Initiated
04/21/25
Truist Financial Initiates a Buy Rating on Adverum Biotechnologies (ADVM)
Mizuho Securities Analyst forecast on ADVM
Graig SuvannavejhMizuho Securities
Mizuho Securities
Buy
Reiterated
02/10/25
Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Gilead Sciences (GILD)
Oppenheimer
$28
Buy
842.76%
Upside
Reiterated
11/05/24
Oppenheimer Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)
Chardan Capital Analyst forecast on ADVM
Keay NakaeChardan Capital
Chardan Capital
Buy
Reiterated
10/16/24
Promising Potential of ADAR RNA Editing Fuels Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ADVM
TipRanks AITipRanks
Not Ranked
TipRanks
$2.5
Sell
-15.82%
Downside
Reiterated
06/07/25
Adverum Biotechnologies' overall stock score is predominantly affected by its poor financial performance and bearish technical indicators. The negative P/E ratio further highlights valuation concerns. The subtenant default situation adds potential operational risks, requiring close monitoring. Immediate improvements in financial health and strategic adjustments are essential for enhancing the stock's prospects.
TD Cowen Analyst forecast on ADVM
Joseph ThomeTD Cowen
TD Cowen
Buy
Reiterated
05/15/25
Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec's Advancements in Wet AMD Treatment
H.C. Wainwright Analyst forecast on ADVM
Matthew CaufieldH.C. Wainwright
H.C. Wainwright
$30
Buy
910.10%
Upside
Reiterated
05/15/25
Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Adverum Biotechnologies (ADVM)
RBC Capital Analyst forecast on ADVM
Lisa WalterRBC Capital
RBC Capital
$5$4
Hold
34.68%
Upside
Reiterated
05/14/25
Adverum Biotechnologies (ADVM) Gets a Hold from RBC Capital
Truist Financial Analyst forecast on ADVM
Joon LeeTruist Financial
Truist Financial
Buy
Initiated
04/21/25
Truist Financial Initiates a Buy Rating on Adverum Biotechnologies (ADVM)
Mizuho Securities Analyst forecast on ADVM
Graig SuvannavejhMizuho Securities
Mizuho Securities
Buy
Reiterated
02/10/25
Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Gilead Sciences (GILD)
Oppenheimer
$28
Buy
842.76%
Upside
Reiterated
11/05/24
Oppenheimer Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)
Chardan Capital Analyst forecast on ADVM
Keay NakaeChardan Capital
Chardan Capital
Buy
Reiterated
10/16/24
Promising Potential of ADAR RNA Editing Fuels Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adverum Biotechnologies

1 Month
xxx
Success Rate
6/16 ratings generated profit
38%
Average Return
+4.06%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of +4.06% per trade.
3 Months
xxx
Success Rate
5/14 ratings generated profit
36%
Average Return
-2.81%
initiated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -2.81% per trade.
1 Year
Joon LeeTruist Financial
Success Rate
3/14 ratings generated profit
21%
Average Return
-46.41%
initiated a buy rating 2 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -46.41% per trade.
2 Years
xxx
Success Rate
1/14 ratings generated profit
7%
Average Return
-65.45%
initiated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -65.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADVM Analyst Recommendation Trends

Rating
Oct 24
Nov 24
Feb 25
Apr 25
May 25
Strong Buy
9
10
8
5
2
Buy
5
5
5
6
4
Hold
1
1
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
16
14
13
8
In the current month, ADVM has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ADVM average Analyst price target in the past 3 months is 17.00.
Each month's total comprises the sum of three months' worth of ratings.

ADVM Financial Forecast

ADVM Earnings Forecast

Next quarter’s earnings estimate for ADVM is -$2.25 with a range of -$2.40 to -$2.06. The previous quarter’s EPS was -$2.25. ADVM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ADVM has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ADVM is -$2.25 with a range of -$2.40 to -$2.06. The previous quarter’s EPS was -$2.25. ADVM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ADVM has Preformed in-line its overall industry.

ADVM Sales Forecast

Next quarter’s sales forecast for ADVM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. ADVM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year ADVM has Preformed in-line its overall industry.
Next quarter’s sales forecast for ADVM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. ADVM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year ADVM has Preformed in-line its overall industry.

ADVM Stock Forecast FAQ

What is ADVM’s average 12-month price target, according to analysts?
Based on analyst ratings, Adverum Biotechnologies’s 12-month average price target is 17.00.
    What is ADVM’s upside potential, based on the analysts’ average price target?
    Adverum Biotechnologies has 472.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ADVM a Buy, Sell or Hold?
          Adverum Biotechnologies has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Adverum Biotechnologies’s price target?
            The average price target for Adverum Biotechnologies is 17.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $4.00. The average price target represents 472.39% Increase from the current price of $2.97.
              What do analysts say about Adverum Biotechnologies?
              Adverum Biotechnologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of ADVM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis